Literature DB >> 26880803

Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.

Douglas E Linn1, Kathryn L Penney2, Roderick T Bronson3, Lorelei A Mucci2, Zhe Li4.   

Abstract

TMPRSS2-ERG gene fusions that occur frequently in human prostate cancers can be generated either through insertional chromosomal rearrangement or by intrachromosomal deletion. Genetically, a key difference between these two mechanisms is that the latter results in deletion of a ∼3-Mb interstitial region containing genes with unexplored roles in prostate cancer. In this study, we characterized two mouse models recapitulating TMPRSS2-ERG insertion or deletion events in the background of prostate-specific PTEN deficiency. We found that only the mice that lacked the interstitial region developed prostate adenocarcinomas marked by poor differentiation and epithelial-to-mesenchymal transition. Mechanistic investigations identified several interstitial genes, including Ets2 and Bace2, whose reduced expression correlated in the gene homologs in human prostate cancer with biochemical relapse and lethal disease. Accordingly, PTEN-deficient mice with prostate-specific knockout of Ets2 exhibited marked progression of prostate adenocarcinomas that was partly attributed to activation of MAPK signaling. Collectively, our findings established that Ets2 is a tumor suppressor gene in prostate cancer, and its loss along with other genes within the TMPRSS2-ERG interstitial region contributes to disease progression. Cancer Res; 76(7); 1869-81. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26880803      PMCID: PMC4873435          DOI: 10.1158/0008-5472.CAN-15-1911

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Ets2-dependent microenvironmental support of mouse mammary tumors.

Authors:  John A Tynan; Fang Wen; William J Muller; Robert G Oshima
Journal:  Oncogene       Date:  2005-10-20       Impact factor: 9.867

4.  Chromosomal protein HMGN1 modulates the expression of N-cadherin.

Authors:  Yaffa R Rubinstein; Takashi Furusawa; Jae-Hwan Lim; Yuri V Postnikov; Katherine L West; Yehudit Birger; Sunmin Lee; Phuongmai Nguyen; Jane B Trepel; Michael Bustin
Journal:  FEBS J       Date:  2005-11       Impact factor: 5.542

5.  N-cadherin switching occurs in high Gleason grade prostate cancer.

Authors:  Meena Jaggi; Tanya Nazemi; Neil A Abrahams; John J Baker; Anton Galich; Lynette M Smith; K C Balaji
Journal:  Prostate       Date:  2006-02-01       Impact factor: 4.104

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.

Authors:  G Foos; C A Hauser
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

8.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

9.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

10.  RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.

Authors:  Maaike P A van Bragt; Xin Hu; Ying Xie; Zhe Li
Journal:  Elife       Date:  2014-11-21       Impact factor: 8.140

View more
  11 in total

1.  Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.

Authors:  Ali Naderi
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-24

Review 2.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

3.  Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Authors:  Kanerva Lahdensuo; Andrew Erickson; Irena Saarinen; Heikki Seikkula; Johan Lundin; Mikael Lundin; Stig Nordling; Anna Bützow; Hanna Vasarainen; Peter J Boström; Pekka Taimen; Antti Rannikko; Tuomas Mirtti
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

4.  ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Authors:  Alba Torres; Mohammed Alshalalfa; Elai Davicioni; Anuj Gupta; Srinivasan Yegnasubramanian; Sarah J Wheelan; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan
Journal:  Prostate       Date:  2018-05-15       Impact factor: 4.104

Review 5.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

Review 6.  Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy.

Authors:  Mankgopo M Kgatle; Asgar A Kalla; Muhammed M Islam; Mike Sathekge; Razia Moorad
Journal:  Prostate Cancer       Date:  2016-11-06

7.  TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.

Authors:  Leonie Ratz; Mark Laible; Lukasz A Kacprzyk; Stephanie M Wittig-Blaich; Yanis Tolstov; Stefan Duensing; Peter Altevogt; Sabine M Klauck; Holger Sültmann
Journal:  Oncotarget       Date:  2017-04-11

8.  Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2.

Authors:  Joshua P Plotnik; Peter C Hollenhorst
Journal:  Nucleic Acids Res       Date:  2017-05-05       Impact factor: 16.971

Review 9.  Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.

Authors:  Sander Frank; Peter Nelson; Valeri Vasioukhin
Journal:  F1000Res       Date:  2018-08-02

10.  MTA1-Dependent Anticancer Activity of Gnetin C in Prostate Cancer.

Authors:  Avinash Kumar; Kshiti Dholakia; Gabriela Sikorska; Luis A Martinez; Anait S Levenson
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.